ID   SUP-B15/RI
AC   CVCL_S642
SY   SUP-B15-RI
DR   Cosmic; 1630018
DR   Wikidata; Q54970860
RX   PubMed=22285507;
RX   PubMed=23230732;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1
DI   ORDO; Orphanet_585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0103 ! SUP-B15
SX   Male
AG   9Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 29-06-23; Version: 13
//
RX   PubMed=22285507; DOI=10.1016/j.leukres.2011.12.018;
RA   Xing H.-Y., Yang X., Liu T., Lin J., Chen X.-Y., Gong Y.-P.;
RT   "The study of resistant mechanisms and reversal in an imatinib
RT   resistant Ph+ acute lymphoblastic leukemia cell line.";
RL   Leuk. Res. 36:509-513(2012).
//
RX   PubMed=23230732;
RA   Lin J., Xing H.-Y., Gong Y.-P., Yang X., Guo Y., Shan Q.-Q.,
RA   Zhou R.-Q.;
RT   "Multidrug resistant gene MDR1 contributes to development of
RT   imatinib-resistance in Ph (+) acute lymphoblastic leukemia cell line
RT   SUP-BS15RI.";
RL   Sichuan Da Xue Xue Bao Yi Xue Ban 43:657-660(2012).
//